Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Casgevy (exa-cel)
Pharma
Bluebird down 18% with slow uptake of SCD gene therapy Lyfgenia
Bluebird appears to be trailing Vertex in their competition to attract patients to their respective gene therapies for sickle cell disease.
Kevin Dunleavy
Aug 14, 2024 12:07pm
NICE signs off on Vertex, CRISPR's Casgevy for beta thalassemia
Aug 7, 2024 8:20pm
Vertex lifts sales guidance as Casgevy launch picks up
Aug 2, 2024 11:34am
Vertex files suit against US over access to fertility program
Jul 16, 2024 7:36am
Long-term data shows durability of Vertex's gene therapy Casgevy
Jun 14, 2024 11:12am
With 64 centers activated, bluebird is ready to grow Lyfgenia
May 9, 2024 1:40pm
